Literature DB >> 8619630

Functional organization of mammalian hexokinases: both N- and C-terminal halves of the rat type II isozyme possess catalytic sites.

H J Tsai1, J E Wilson.   

Abstract

Previous work has shown that catalytic function is associated exclusively with the C-terminal half of the Type I isozyme of mammalian hexokinase. In contrast, we now demonstrate that both halves of the Type II isozyme possess comparable catalytic activities. Mutation of a catalytically important Ser residue to Ala at analogous positions in either the N- or the C-terminal halves (S155A or S603A, respectively) of the rat Type II isozyme resulted in approximately 60% reduction in specific activity of the enzyme, with more than 90% reduction in the doubly mutated enzyme (S155A/S603A). Catalytic activity was retained in a chimeric hexokinase comprising the N-terminal half of Type II hexokinase and catalytically inactive (by site-directed mutation) C-terminal half of the Type I isozyme. The N- and C-terminal catalytic sites of Type II hexokinase are similar in V(max) and K(m) (approximately equal to 130 microM) for glucose; however, the N-terminal site has a lower (0.45 vs 1.1 mM) K(m) for ATP, is slightly more sensitive to inhibition by the product analog 1,5-anhydroglucitol-6-P, and is much more sensitive to inhibition by P(i). It is suggested that the Type II isozyme most closely resembles the 100-kDa hexokinase which resulted from duplication and fusion of a gene encoding an ancestral 50-kDa hexokinase and which was the precursor for the contemporary Type I, Type II, and Type III mammalian isozymes. Subsequent evolutionary changes could then have led to functional differentiation of the N- and C-terminal halves, as seen with the Type I (and possibly the Type III) isozyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8619630     DOI: 10.1006/abbi.1996.0186

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  22 in total

Review 1.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

Review 2.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

3.  Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region.

Authors:  A Ruzzo; F Andreoni; M Magnani
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

Review 4.  Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.

Authors:  S P Mathupala; Y H Ko; P L Pedersen
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

5.  Bovine hexokinase type I: full-length cDNA sequence and characterisation of the recombinant enzyme.

Authors:  Francesca Andreoni; Giordano Serafini; Maria Elena Laguardia; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 6.  The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Biochim Biophys Acta       Date:  2010-04-08

Review 7.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

Review 8.  Evolution of glucose utilization: glucokinase and glucokinase regulator protein.

Authors:  David M Irwin; Huanran Tan
Journal:  Mol Phylogenet Evol       Date:  2013-09-25       Impact factor: 4.286

Review 9.  Homologous and heterologous interactions between hexokinase and mitochondrial porin: evolutionary implications.

Authors:  J E Wilson
Journal:  J Bioenerg Biomembr       Date:  1997-02       Impact factor: 2.945

Review 10.  The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.

Authors:  J Azevedo-Silva; O Queirós; F Baltazar; S Ułaszewski; A Goffeau; Y H Ko; P L Pedersen; A Preto; M Casal
Journal:  J Bioenerg Biomembr       Date:  2016-07-25       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.